SCANCELL LTD has a total of 90 patent applications. It increased the IP activity by 300.0%. Its first patent ever was published in 1997. It filed its patents most often in United Kingdom, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are CANCER ADVANCES INC, YOUNG DAVID S F and ARACLON BIOTECH SL.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 16 | |
#2 | WIPO (World Intellectual Property Organization) | 12 | |
#3 | EPO (European Patent Office) | 9 | |
#4 | Canada | 8 | |
#5 | United States | 8 | |
#6 | Australia | 7 | |
#7 | China | 7 | |
#8 | Brazil | 5 | |
#9 | Republic of Korea | 5 | |
#10 | South Africa | 5 | |
#11 | Singapore | 3 | |
#12 | Hong Kong | 2 | |
#13 | India | 1 | |
#14 | Japan | 1 | |
#15 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Foods and drinks | |
#5 | Organic fine chemistry | |
#6 | Machines |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Analysing materials | |
#6 | Enzymes | |
#7 | Sugars | |
#8 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Durrant Linda Gillian | 61 |
#2 | Brentville Victoria Anne | 27 |
#3 | Metheringham Rachel Louise | 22 |
#4 | Metheringham Rachael Louise | 14 |
#5 | Parsons Tina | 12 |
#6 | Pudney Victoria Anne | 11 |
#7 | Ellis John Robert Maxwell | 6 |
#8 | Xue Wei | 4 |
#9 | Victoria Anne Brentville | 3 |
#10 | Robins Adrian | 3 |
Publication | Filing date | Title |
---|---|---|
GB202101435D0 | Nucleic acids and polypeptides encoded thereby | |
GB202018395D0 | Immunotherapy | |
GB202013385D0 | Nucleic acids and polypeptides encoded thereby | |
GB202005779D0 | Anti-tumour immune responses | |
GB201912882D0 | Ssea-4 binding members | |
GB201912657D0 | Binding members | |
GB201910900D0 | Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof | |
GB201910899D0 | Binding members | |
GB201815041D0 | Epitopes | |
GB201512703D0 | Anti-tumour immune responses to modified self-epitopes | |
GB201214007D0 | Anti-tumour immune responses to modified self-epitopes | |
GB0706070D0 | Nucleic acids | |
GB0410627D0 | Specific binding members | |
ZA200208739B | Humanised antibodies to the epidermal growth factor receptor. | |
GB0111628D0 | Binding member | |
GB0102145D0 | Substances | |
GB0020794D0 | Humanised antibodies |